Targeting MEX3A or KLF4 not only suppressed CRC cell proliferation, but also increased their differentiation status, suggesting that it might represent a new potent target for cancer differentiation therapy upon CRC. The gene discussed is MEX3A; the disease is colorectal carcinoma.